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Abstract
Background
Smoking is a recognized risk factor for osteoporosis. Trabecular bone score (TBS) is a
novel texture parameter to evaluate bone microarchitecture. TBS and their main determi-
nants are unknown in active and former smokers.
Objective
To assess TBS in a population of active or former smokers with and without Chronic
Obstructive Pulmonary Disease (COPD) and to determine its predictive factors.
Methods
Active and former smokers from a pulmonary clinic were invited to participate. Clinical fea-
tures were recorded and bone turnover markers (BTMs) measured. Lung function, low dose
chest Computed Tomography scans (LDCT), dual energy absorptiometry (DXA) scans
were performed and TBS measured. Logistic regression analysis explored the relationship
between measured parameters and TBS.
Results
One hundred and forty five patients were included in the analysis, 97 (67.8%) with COPD.
TBS was lower in COPD patients (median 1.323; IQR: 0.13 vs 1.48; IQR: 0.16, p = 0.003).
Regression analysis showed that a higher body mass index (BMI), younger age, less num-
ber of exacerbations and a higher forced expiratory volume-one second (FEV1%) was asso-
ciated with better TBS (β = 0.005, 95% CI:0.000–0.011, p = 0.032; β = -0.003, 95% CI:-
0.007(-)-0.000, p = 0.008; β = -0.019, 95% CI:-0.034(-)-0.004, p = 0.015; β = 0.001, 95%
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CI:0.000–0.002, p = 0.012 respectively). The same factors with similar results were found in
COPD patients.
Conclusions
A significant proportion of active and former smokers with and without COPD have an
affected TBS. BMI, age, number of exacerbations and the degree of airway obstruction pre-
dicts TBS values in smokers with and without COPD. This important information should be
considered when evaluating smokers at risk of osteoporosis.
Introduction
Osteoporosis affects an estimated 200 million people, being a major cause of morbidity and
mortality worldwide and resulting in approximately 9 million new fractures annually [1]. The
agreed international definition of osteoporosis [2] highlights the notion that both low bone
mineral density (BMD) and other bone abnormalities such as microarchitectural impairment
contribute to skeletal fragility. However, the diagnosis of osteoporosis is based solely on the
measurement of BMD by dual energy absorptiometry (DXA) scan [3]. Interestingly, an
impaired bone microarchitecture, independent of BMD, is also associated with a greater risk
of bone fracture [4]. Therefore, it is recognized that the evaluation of bone microarchitecture
might enhance the accuracy of risk fracture assessment.
Lumbar spine trabecular bone score (TBS) was developed as an innovative grey-level tex-
ture parameter that can be applied to DXA acquisitions. TBS is calculated from experimental
variograms of the 2D projection DXA images, quantifying variation in grey-level texture as a
function of distance from one pixel to the others. It is not exactly a measurement of bone
microarchitecture, but approximately represents the 3D bone characteristics: trabecular sepa-
ration, trabecular number, and connectivity density [4,5]. Therefore, higher TBS corresponds
to more homogeneously textured bone, representing strong and fracture resistant microarchi-
tecture and vice versa. This novel score does not require further patient tests and is easily cal-
culated in seconds by commercially available software applied prospectively or retrospectively
to standard DXA images [6].
Smoking has long been identified as a risk factor for osteoporosis, with studies showing that
older smokers have decreased bone mineral density measured by DXA scan and increased
fracture risk compared to nonsmokers, particularly at the hip [7]. Moreover, the increase in
fracture risk in this population is out of proportion to the alterations seen on bone density; this
indicates, perhaps, a deficiency in bone quality [8].
To better understand the potential clinical utility of TBS in smokers, the main objective of
this study is to describe TBS and its predictive factors in a population of active and former
smokers with and without COPD.
Materials and methods
Participants
Study subjects were active and former smokers evaluated at the pulmonary clinic of Clı´nica
Universidad de Navarra between August 2014 and March 2016. Invited patients were men and
postmenopausal women, 50 years of age or older, with a smoking history of�10 pack-years.
Previous diagnosis of osteoporosis, use of preventive osteoporosis treatment and�6 month
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between the DXA scan and the blood draw were the exclusion criteria. All subjects signed a
consent form previously approved by the Institution’s ethics committee (Comite de E´tica Clı´n-
ica Universidad de Navarra, n˚151/2014).
The initial visit included a complete medical history, physical examination, blood samples
collection, pulmonary function tests (PFTs), 6 minute walking distance (6MWD), BMD mea-
surement and a low-dose chest computed tomography (LDCT). A questionnaire was adminis-
tered by a single investigator including age, race, body mass index (BMI), menopause
information, personal and family fracture history, tobacco and alcohol intake history, medica-
tion use in the past and present (including oral and inhaled corticosteroids) and number of
respiratory exacerbations. Respiratory exacerbations were defined as an acute worsening of
respiratory symptoms (cough, sputum production, dyspnea, wheezing) which result in the use
of additional therapy [9,10], as defined by global initiative for chronic obstructive lung disease
(GOLD) [11].
Fig 1 shows the Flowchart of the included individuals.
Pulmonary function tests (PFTs)
PFTs (spirometry, lung volumes and diffusing capacity) were performed with a flow spirome-
ter (Vmax22; SensorMedics, Yorba Linda, CA) according to the American Thoracic Society
guidelines [12]. The European Community Lung Health Survey values were used as a refer-
ence [13]. Post bronchodilation measurements were determined 15´ after the inhalation of
400 μg of albuterol. The presence and severity of airflow limitation was determined using the
GOLD definition and spirometric classification [11]. The latter is based on the predicted post-
bronchodilator forced expiratory volume-one second (FEV1) and is composed of four groups:
1 (FEV1�80%), 2 (50–80%), 3 (30–50%), and 4 (<30%). The 6MWD was performed following
the American Thoracic Society guidelines [14].
Bone density by Dual X-ray absorptiometry
Bone mineral density of the lumbar spine (L1 to L4), femoral neck, total hip and in some cases
non-dominant forearm (33%) were measured in every patient using a dual X-ray absorptiome-
try (DEXA) technique with a Lunar iDXA scan (General Electric Co). Results were expressed
in g/cm2 and a T-score was calculated as the number of standard deviations above or below
Fig 1. Study design. Flowchart showing the inclusion of the participants.
https://doi.org/10.1371/journal.pone.0209777.g001
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the young normal reference mean BMD. Diagnosis of osteoporosis was based on the World
Health Organization (WHO) criteria [15].
Trabecular bone score (TBS)
Lumbar spine TBS was obtained using the DXA images of each patient. TBS was calculated
using TBS iNsight software (Version 2.2.0, Med-Imaps, Bordeaux, France) by one of the
authors (MR) who was blinded to the clinical data of the participants. Since there is a lack of
reference values for TBS in a Mediterranean population like the present one, we used the three
categories recommended by the software provider (iNsight): 1) normal microarchitecture:
TBS�1.300; 2) partially deteriorated microarchitecture: TBS<1.300 and >1.200 and 3)
degraded microarchitecture: TBS�1.200.
Low dose chest CT (LDCT)
LDCT examinations were obtained with the patient in supine position, in cranio-caudal direc-
tion and at end-inspiration.
Patients were studied with a 64 slice multidetector CT scanner (Somatom Sensation 64,
Somatom Definition, Siemens Healthcare, Erlangen, Germany), also at a low-dose setting (120
kV tube voltage, 40 mAs tube current, 64x0.6 mm slice collimation, 0.5 s gantry rotation time,
1.4 pitch, 1 mm slice thickness, 1 mm reconstruction interval).
Assessment of emphysema on LDCT
Emphysema was visually assessed in the chest CT by one reader (JG) for presence, type and
severity, using a validated criteria established by the Fleischner Society [16]. Scoring proce-
dures used a five-level semi quantitative scale based on criteria used in the National Emphy-
sema Treatment Trial [17].
Biochemistry
All the samples were drawn in all patients early in the morning of the visit day and in fasting
status. Samples were collected into Vacutainer tubes, and aliquots were stored frozen at -80˚C
until analysis. Measurements of BTM were performed at the Laboratory of Biochemistry of the
Clı´nica Universidad de Navarra. Details of the measurements have been previously described
[18].
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences version
20.0 (SPSS Inc). Normal distribution was assessed by the Shapiro-Wilks test. Quantitative data
are represented as mean ± SD or median (interquartile range), depending on the data distribu-
tion; relative frequencies were used for qualitative data. Differences between study groups
were evaluated by the Student’s t test, Mann-Whitney U test, and χ2 statistics accordingly. Sim-
ple bivariate Pearson correlation coefficients were examined between TBS and other continu-
ous variables (age, BMI, lumbar spine BMD), showing a weak inverse correlation with age
(-0.25), a moderate positive correlation with BMI (0.33) and a strong positive correlation with
lumbar spine BMD (0.56). Uni and multivariable linear regression analysis with TBS as a
dependent variable were performed to study the potential independent association of the stud-
ied parameters. The multivariable linear regression analysis included those variables that were
statistically significant in the univariable analysis and those clinically soundable. Two multivar-
iable analyses were performed, one in the entire population and another focused on COPD
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patients. All analysis was adjusted for age, sex, body mass index (BMI) and lumbar spine
BMD, based on the correlation analysis.
Results
The study population characteristics are shown in Table 1. This study sample included patients
in their 6th decade with a slight predominance of males (56%) and somewhat overweight
(mean 27.2 Kg/m2). Two thirds of the patients met COPD criteria with a mild degree of airway
limitation.
Emphysema was visually detected in 56.5% of the population, with centrilobular and para-
septal (47.5%) being the most frequent type, followed by centrilobular alone (44%) and para-
septal alone (8.5%). The majority of the population had low bone mass according to WHO
criteria (51%) and 23.4% had osteoporosis. In 13 patients, the BTM levels could not be
measured.
Median TBS in our population was 1.334. The distribution of the different categories of
TBS levels by the results of DXA scan is shown in Table 2. Importantly, 55 out of 145 (38%)
smokers had abnormal TBS values (<1.300) and we also highlight that 8.3% of the patients
with normal densitometry values have TBS values in the range of partially deteriorated and
degraded microarchitecture. Interestingly, we found that 56 patients (62%) with normal TBS
values were diagnosed with osteopenia and osteoporosis using the DXA scan.
Table 3 shows the comparison of smokers with and without COPD. COPD patients were
significantly older and had a lower BMI. Moreover, there was a higher proportion of active
smokers with a higher smoking history. As expected, emphysema was more frequent and
more severe in COPD patients. A main finding was that COPD patients had lower TBS (1.3±
0.13 vs 1.4 ±0.16, p = 0.003) compared with smokers without COPD. Comparing BTMs, we
only found statistically significant differences in P1NP values (35.2±19.6 vs 41.5±30.6 respec-
tively, p = 0.0045).
Table 4 shows the independent association of each studied parameter with TBS. Age, FEV1,
higher BMI and number of exacerbations were associated with higher TBS values. Table 5
shows this association but only in those with COPD. The same predictors were found in both
groups.
Discussion
The most important and novel information of the present study is that it reports for the first
time TBS values in a high risk population of active and former smokers with and without
COPD. We found lower TBS in COPD patients and, interestingly, that at least 40% of the stud-
ied individuals have abnormal (<1.300) TBS values, which the literature reported to be associ-
ated with an increased risk of major osteoporotic fracture, independent of BMD values
[19,20,21,22,23]. We also found that the best predictors of TBS values were lung function,
number of exacerbations, age and BMI. Moreover, TBS values were, as expected, lower in
women than in men, but only in smokers without COPD, after adjusting for other relevant
factors.
It is well known that one of the most common extra pulmonary manifestations of COPD is
osteoporosis [24,25,26]. The present study showed that patients with COPD attending a pul-
monary clinic have lower TBS compared with those without. This is in line with a study per-
formed on 61 COPD males, where BMD and TBS were independently associated with 2 or 3
vertebral fractures in these patients [27]. Similarly, in a study that explores the clinical factors
associated with trabecular bone score in 29.047 postmenopausal women from Manitoba,
COPD was statistically significant in the multiple linear regression analysis [28]. This is also in
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agreement with previous findings indicating that COPD patients have reduced bone stiffness
and failure load estimated by finite elements analysis based on in-vivo high resolution images
of the distal radius and tibia [14]. Furthermore, a recent study in postmenopausal women with
COPD demonstrated that the microarchitectural deterioration could be evidenced by low tra-
becular number, connectivity, and thickness, additionally with an increase in trabecular spac-
ing [29]. Therefore, the evaluation reporting reduced TBS values in these COPD patients
Table 1. Baseline clinical, bone remodeling markers and densitometry characteristics of the study population.
Characteristics N = 145
Demographic
Age years-old, Mean (SD) 63 (8)
Male, No(%) 81 (56)
BMI Kg/m2, Mean (SD) 27.2 (4.6)
Clinical
Diabetes 20 (13.8)
Active smoker, No (%) 69 (48)
Pack-years of smoking, Median (IQR) 40.5 (28.5)
Emphysema, No (%) 82 (56.5)
Severity of emphysema by NETT (0–4), Median (IQR) 1(2)
Inhaled steroids, No (%) 37 (26)
COPD, No (%) 97 (67.8)
BODE index for COPD patients, Median (IQR) 0 (1)
Post-Bronchodilator spirometry
FVC-L, Mean (SD) 3.66 (1.2)
FVC-%, Mean (SD) 115 (23.9)
FEV1-L, Mean (SD) 2.13 (0.8)
FEV1-%, Mean (SD) 83.1 (23.7)
FEV1/FVC, Median (IQR) 61.5 (19)
Additional Pulmonary Functional Test
6MWD-meters, Median (IQR) 515 (101)
Bone-Remodeling Marker Levels
CTX ng/mL, Median (IQR) 0.27 (0.21)
Osteocalcin ng/mL, Median (IQR) 14.72 (8.8)
P1NP ng/mL, Median (IQR) 37.6 (20.5)
25-Hydroxy Vitamin D ng/mL, Median (IQR) 20.77 (18.6)
Densitometry Results
Densitometry results according WHO
Normal, No (%) 37 (25.5)
Osteopenia, No (%) 74 (51.0)
Osteoporosis, No (%) 34 (23.4)
Trabecular bone score, Median (IQR) 1.334 (0.14)
Trabecular bone score <1.300 n, % 55 (38.2)
SD = standard deviation; BMI = body mass index; IQR = interquartil range (25–75 percentile); COPD = Chronic
Obstructive Pulmonary Disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; BODE = Body-
mass index, airflow Obstruction, Dyspnea, and Exercise; NETT = national emphysema treatment trial; 6WMT = six
minutes walking test; FRAX = Fracture Risk Assessment Tool score; CTX = C-terminal telopeptide of type I collagen;
P1NP = N-terminal propeptide of type 1 procollagen; BMD = bone mineral density; WHO = World Health
Organization; FVC = forced vital capacity; FEV1 = forced expiratory volume-one second; TBS = trabecular bone
score; No = number.
https://doi.org/10.1371/journal.pone.0209777.t001
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could imply that they have decreased bone strength [30], placing them at an increased fracture
risk [31,32].
The present work also found that lung function, age and BMI were the most important fac-
tors associated with TBS values in this population. Lung function represented by FEV1% was
one of the most important factors independently associated with TBS values in the entire pop-
ulation and in COPD patients. Previous studies have also demonstrated an association
Table 2. Distribution of the different TBS categories by DXA results.
Densitometry results according to WHO criteria
Normal Osteopenia Osteoporosis
Diagnosis by TBS in column �1.300 34 (91.2%) 47 (63.5%) 9 (26.5%)
1.200–1.300 1 (2.7%) 23 (31.1%) 16 (47%)
�1.200 2 (5.4%) 4 (5.4%) 9 (26.5%)
TBS = trabecular bone score; DXA = dual energy absorptiometry.
https://doi.org/10.1371/journal.pone.0209777.t002
Table 3. Baseline clinical, bone remodeling markers and densitometry characteristics of patients with and without
COPD.
Characteristics COPD
(n = 99)
No COPD
(n = 46)
p Value
Demographic
Age years-old, Mean (SD) 64.3 (8.1) 60.1 (7.01) 0.003
Male, No (%) 55 (56.1) 26 (56.5) 0.960
BMI Kg/m2, Mean (SD) 26.7 (4.5) 28.2 (4.8) 0.080
Clinical
Active smoker, No (%) 37 (37.4) 32 (69.6) 0.000
Pack-years of smoking, Median (IQR) 49.3 (31.2) 38.9 (19.7) 0.040
Emphysema, No (%) 64 (68.3) 18 (39.1) 0.004
Severity of emphysema, by NETT (0–4), Median (IQR) 1 (2) 0 (1) 0.000
Inhaled steroids, No (%) 35 (36) 2 (4.4) 0.000
Bone-Remodeling Marker Levels
CTX ng/mL, Median (IQR) 0.26 (0.19) 0.31 (0.22) 0.141
Osteocalcin ng/mL, Median (IQR) 14.2 (7.9) 16.5 (10.4) 0.221
P1NP ng/mL, Median (IQR) 35.2 (19.6) 41.5 (30.6) 0.004
25-Hydroxy Vitamin D ng/mL, Median (IQR) 20.3 (17.3) 24 (20.4) 0.461
Densitometry Results
Densitometry results according to WHO
Normal, No (%) 22 (22.2) 15 (32.6)
Osteopenia, No (%) 51 (51.5) 23 (50)
Osteoporosis, No (%) 26 (26.2) 8 (17.4) 0.300
a
Trabecular bone score, Median (IQR) 1.323 (0.13) 1.480 (0.16) 0.003
Trabecular bone score <1.300 n, % 45 (45.9) 10 (21.7) 0.005
COPD = Chronic Obstructive Pulmonary Disease; SD = standard deviation; BMI = body mass index;
IQR = interquartil range (25–75 percentile); NETT = national emphysema treatment trial; CTX = C-terminal
telopeptide of type I collagen; P1NP = N-terminal propeptide of type 1 procollagen; BMD = bone mineral density;
WHO = World Health Organization; TBS = trabecular bone score.
achi2 Test between Osteoporosis diagnosis and study groups (COPD vs no COPD).
https://doi.org/10.1371/journal.pone.0209777.t003
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between pulmonary function and bone density or bone architecture in COPD patients [33].
Moreover, Kulak et al. showed that patients with a more severe degree of airway limitation
(GOLD spirometric grades 3 and 4) presented a significantly lower bone formation rate when
compared with patients with mild to moderate disease (0.028±0.009 versus 0.016±0.011 μm3/
μm2/day, p = .04)(29). Misof et al., also found that heterogeneity of cancellous bone minerali-
zation was significantly lower in the most severe COPD patients (GOLD III and IV) [34].
As also reported in the general population, lower BMI is associated with a lower TBS [35].
A low BMI is usually present in approximately 15–20% of COPD patients [36] and it also plays
an important role in osteoporosis and risk fracture [37,38]. COPD patients are predisposed to
low body weight due to multiple reasons including malnutrition, depression and hyper-catab-
olism related to increased energy cost (breathing, tissue hypoxia, use of beta-agonist, and
Table 4. Linear regression analysis with TBS as a dependent variable in all patients.
Variables β IC 95% P value
Univariate analysis
Age years-old -0.004 -0.006-(-)0.001 0.003
Male 0.070 0.032–0.107 0.000
BMI Kg/m2 0.008 0.004–0.012 0.000
Pack-years -0.000 -0.001–0.000 0.084
Smoking status 0.021 -0.017–0.059 0.275
Emphysema -0.060 -0.098-(-)0.021 0.002
Severity of emphysema, by NETT (0–4) -0.032 -0.049-(-)0.015 0.000
COPD -0.060 -0.099-(-)0.020 0.004
BODE -0.029 -0.041-(-)0.017 0.000
Post-bronchodilator FEV1 (%) 0.001 0.000–0.002 0.002
DLCO (ml/min/mmHg) 0.002 0.001–0.003 0.000
6MWT meters 0.000 0.000–0.001 0.000
Number of exacerbations -0.034 -0.050-(-)0.017 0.000
Inhaled CT -0.060 -0.102-(-)0.178 0.006
Oral CT -0.135 -0.210-(-)0.060 0.000
CTX-I ng/mL -0.151 -0.258-(-)0.044 0.006
P1NP -0.000 -0.001–0.000 0.430
Lumbar spine DMO 0.327 0.247–0.406 0.000
Multivariate analysisa
Age -0.003 -0.007-(-)0.000 0.008
BMI Kg/m2 0.005 0.000–0.011 0.032
Male 0.012 -0.044–0.076 0.956
Oral CT 0.022 -0.049–0.093 0.535
Inhaled CT 0.006 -0.036–0.048 0.768
6MWD meters -0.000 -0.000–0.000 0.830
Post-bronchodilator FEV1 (%) 0.001 0.000–0.002 0.012
Number of exacerbations -0.019 -0.034(-)-0.004 0.015
Emphysema 0.000 -0.043–0.045 0.964
CTX-I ng/mL 0.023 -0.095–0.142 0.695
Lumbar spine DMO 0.332 0.205–0.459 0.000
COPD = Chronic Obstructive Pulmonary Disease; BMI = body mass index; NETT = national emphysema treatment
trial; FEV1 = forced expiratory volume-one second; DLCO = diffusing capacity for carbon monoxide; 6WMT = six
minutes walking test; CTX = C-terminal telopeptide of type I collagen; CT = corticosteroids.
a All the variables included in the multivariable analysis are shown in the table.
https://doi.org/10.1371/journal.pone.0209777.t004
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chronic systemic inflammation) [39,40,41]; therefore, it is not a surprise that the present study
results indicate that it is also associated with low TBS.
The independent association between exacerbations and TBS values is another finding
from the present study. Exacerbations play an important role in COPD patients because they
have negative impacts in several aspects, such as pulmonary function [42,43], health status
[10], survival [44,45], the BODE index [46] and also socioeconomic cost [47]. This impact also
affects and causes deterioration in risk facts related to osteoporosis. In this regard, exacerba-
tions are associated with physical inactivity [46], systemic inflammation [48] and the use of
corticosteroids. A longitudinal study of 42 COPD patients demonstrated that patients with a
history of exacerbations have a higher decrease in bone mineral density assessed on chest com-
puted tomography compared with those without a history of exacerbations [49].
Table 5. Linear regression analysis with TBS as a dependent variable in COPD patients.
Variables β IC 95% P value
Univariate analysis
Age years-old -0.003 -0.006–0.000 0.047
Male 0.067 0.024–0.110 0.003
BMI Kg/m2 0.006 0.001–0.011 0.022
Pack-years -0.000 -0.001–0.000 0.440
Smoking status 0.021 -0.024–0.068 0.355
Post-bronchodilator FEV1 (%) 0.053 0.026–0.081 0.000
DLCO (ml/min/mmHg) 0.002 0.001–0.004 0.001
BODE -0.029 -0.041(-)-0.017 0.000
Emphysema -0.050 -0.097-(-)0.004 0.032
Severity of emphysema, by NETT (0–4) -0.027 -0.453-(-)0.007 0.006
6MWD-meters 0.000 0.000–0.001 0.000
Number of exacerbations -0.029 -0.046-(-)0.112 0.001
Inhaled CT -0.060 -0.1059-(-)0.016 0.009
Oral CT -0.120 -0.193–0.047 0.002
CTX ng/mL -0.166 -0.291-(-)0.040 0.010
P1NP -0.000 -0.002–0.001 0.584
Lumbar spine BMD 0.330 0.241–0.419 0.000
Multivariate analysisa
Age -0.004 -0.006(-)-0.001 0.007
Male -0.007 -0.055–0.039 0.752
BMI Kg/m2 0.005 0.000–0.009 0.026
6MWD-meters -0.000 -0.000–0.000 0.878
Post-bronchodilator FEV1 (%) 0.001 0.000–0.002 0.007
Emphysema 0.011 -0.034–0.057 0.625
Lumbar spine BMD 0.319 0.185–0.452 0.000
Number of exacerbations -0.021 -0.037(-)-0.005 0.011
Inhaled CT 0.004 -0.040–0.048 0.854
Oral CT 0.023 -0.049–0.096 0.519
CTX ng/mL 0.009 -0.114–0.133 0.875
COPD = Chronic Obstructive Pulmonary Disease; BMI = body mass index; NETT = national emphysema treatment
trial; FEV1 = forced expiratory volume-one second; DLCO = diffusing capacity for carbon monoxide; 6WMT = six
minutes walking test; CTX-I = C-terminal telopeptide of type I collagen.
a All the variables included in the multivariable analysis are shown in the table.
https://doi.org/10.1371/journal.pone.0209777.t005
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Interestingly, TBS is abnormal (<1.300) in a significant proportion of the smokers (40%)
which did not exactly match with the ones that had abnormal BMD values (Table 1), suggest-
ing the complementary role of this technique in evaluating risk fracture in this high risk popu-
lation. We found two scenarios that confirmed the complementary information provided by
BMD and TBS: 47 (63.5%) patients diagnosed with osteopenia by DXA had normal TBS and 9
(26.5%) osteoporotic patients by DXA scan had normal TBS. These results suggest that these
techniques provide different information about bone status, indicating that they are comple-
mentary and maybe useful to identify individuals at risk of bone fracture. Further studies
should explore the potential complementary role of these techniques to better identify those
smokers at high risk for bone fractures.
The present study has limitations. Firstly, this is a highly selected population of smokers
from a tertiary academic Pulmonary Clinic; therefore, results should be confirmed in other
populations. Secondly, this is a relatively small population lacking a never-smoker control
group to complete the entire spectrum of population types, this could have helped us deter-
mine the normal values representative of our local population. Thirdly, fortunately these
patients are currently under follow up to determine if those with abnormal TBS values and
normal bone mineral density will develop bone fractures, enabling us to provide that relevant
information.
Conclusions
A significant proportion of active and former smokers with and without COPD have an
affected TBS, an easy way to measure skeletal microarchitecture and therefore, a potential pre-
dictor of risk fracture. Lung function, age, BMI and number of exacerbations were their main
predictors. TBS seems to provide complementary information in the evaluation of risk fracture
in this high-risk population. Further studies should validate these important findings.
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